<DOC>
	<DOCNO>NCT02254954</DOCNO>
	<brief_summary>This prospective , single-center , open-label , 3+3 dose escalation Phase 1 safety study . Adults newly diagnose GBM gliosarcoma receive macitentan addition standard care treatment GBM . The study consist screen period , treatment period , 30-day safety follow period . The treatment period include 6 week concurrent therapy ( macitentan+RT+TMZ ) , 4 week monotherapy ( macitentan ) 12 cycle maintenance therapy ( macitentan+TMZ ) . The study end last treated subject complete study treatment 30-day safety follow-up period . The planned duration study approximately 34-38 month depend number dose level cohorts subject enrol . Subject participation study approximately 16 month .</brief_summary>
	<brief_title>Clinical Study Macitentan , RT TMZ Concurrent Therapy Followed Maintenance Macitentan TMZ Newly Diagnosed Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Subjects least 18 year age Histologically proven supratentorial GBM gliosarcoma Use effective contraception woman childbearing potental . Use effective contraception fertile male female partner childbearing potential . Interval least 3 week biopsy open surgery able begin study treatment . Result postoperative contrastenhanced brain MRI within 72 hour surgery biopsy . Adequate bone marrow function Karnofsky Performance Score least 70 . Prior treatment glioblastoma gliosarcoma . Evidence leptomeningeal spread glibolastoma gliosarcoma . Tumor foci tentorium beyond cranial vault . Evidence recent hemorrhage postoperative contrast enhance brain MRI ( except hemosiderin , resolve hemorrhage change relate surgery , presence punctuate hemorrhage tumor ) . Aspartate aminotransferase alanine aminotransferase &gt; 3 time upper limit normal . Supine systolic blood pressure &lt; 100 mmHg diastolic blood pressure &lt; 50 mmHg . Medical history orthostatic hypotension . International normalized ratio &gt; 1.5 anticoagulant therapy , active bleeding low molecular weight heparin , chronic condition high risk bleeding . Severe renal impairment . Severe hepatic impairment . Severe , active comorbidity : ( e.g . cardiac disease ; respiratory disease ; chronic hepatitis ; hemtological bone marrow diseases ; severe malabsoprtion ; human immunodeficiency virus ) . No concurrent strong CYP3A4 inducer inhibitor . No investigational drug within 4 week start study treatment . Any lifethreatening condition could affect protocol compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>glioblastoma</keyword>
</DOC>